Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.53)
# 802
Out of 5,182 analysts
35
Total ratings
57.14%
Success rate
29.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $163.06 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $3.96 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $135.98 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $2.27 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint | Reiterates: Overweight | n/a | $13.60 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.70 | +17.65% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $2.37 | +1,292.41% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.49 | +202.01% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.55 | +3,821.57% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $163.06
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.96
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $135.98
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.27
Upside: -
EyePoint
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.60
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.70
Upside: +17.65%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $2.37
Upside: +1,292.41%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.49
Upside: +202.01%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.55
Upside: +3,821.57%